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ABSTRACT
Reduced-intensity conditioning has extended the use of allogeneic hematopoietic stem cell transplantation
(HSCT) to patients otherwise not eligible for this treatment due to older age or frailty. One hundred twelve
acute myelogenous leukemia/myelodysplastic syndromes patients received fludarabine and melphalan (FM)
conditioning with allogeneic HSCT. Most patients (73%) were not in remission. Graft-versus-host disease
(GVHD) prophylaxis consisted of tacrolimus and mini-methotrexate. Median age was 55 years (range, 22-74).
Donors were related (53%) and unrelated (47%). Median follow-up of surviving patients (n  43) was 29.4
months (range, 13.1-87.7). The complete remission (CR) rate was 82%. Estimates of 2-year survival were 66%,
40%, and 23% for patients in CR, with active disease without and with circulating blasts at HSCT, respectively.
In multivariate analysis, survival was negatively influenced by active disease at HSCT and development of grade
II-IV acute GVHD. Presence of circulating blasts at HSCT negatively influenced freedom from disease
progression. Incidence of nonrelapse mortality (NRM) was significantly higher for patients with active disease,
but was not influenced by patient age. Patients in CR had a day-100 and 2-year NRM of 0% and 20%,
respectively. Use of unrelated donors increased the risk of NRM only among patients with active disease. FM
and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort.
© 2007 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Chemotherapy- or radiation-based preparative
egimens used prior to allogeneic hematopoietic stem
ell transplantation (HSCT) deliver different degrees
f direct antileukemic activity and host immunosup-
ression. The graft provides an immune-mediated
raft-versus-leukemia (GVL) effect. Use of myeloab-
ative conditioning regimens has traditionally been
imited to younger patients without major comorbidi-
ies, given the high rates of treatment-related morbid-
ty and mortality. In addition, ablative regimens are c
54ssociated with a relatively high rate of graft-versus-
ost disease (GVHD), a complication that is to some
xtent precipitated by toxicity, inﬂammation, and
rgan damage inﬂicted by the chemo or radiation
herapy [1,2].
Acute myelogenous leukemia (AML) and myelo-
ysplastic syndromes (MDS) are diseases of the el-
erly, with the median age at diagnosis in the 7th
ecade of life. The age-speciﬁc incidence rate per
00,000 goes from 1.8 to 16.3, for subjects under and
bove age 65, respectively. Unfortunately, results of
hemotherapy are dramatically worse in the elderly,
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HSCT for Treatment of High-Risk Acute Myelogenous Leukemia 455ompared to younger patients. Five-year survival rates
re typically 15%-20% for patients older than 55 years
3,4]. Aging is associated with multiple biologic
hanges that decrease the tolerance to chemotherapy
eading to high rates of toxicity. Furthermore, myeloid
eukemias in the elderly are morel likely to have un-
avorable cytogenetic and molecular abnormalities,
nd are intrinsically less sensitive to current available
herapies [3-5].
Allogeneic transplantation offers higher cure rates
or AML and MDS, but the applicability of the pro-
edure to the majority of patients in need is severely
imited by high rates of toxicity. Over the last 10
ears, the development of reduced intensity regi-
ens has allowed extending the use of allogeneic
ransplantation to older and frailer patients not con-
idered eligible for ablative conditioning. Given the
ower cytoreduction produced by a reduced inten-
ity regimen, this strategy relies on the GVL effect
o eradicate the malignancy [6,7]. Furthermore, he-
atologic malignancies have different sensitivities
o GVL effects, and AML and MDS are considered to
e of intermediate sensitivity [8,9]. Therefore, some
egree of cytoreduction is an important part of treat-
ent of these diseases. We previously reported that
ncreasing myelosuppressive intensity of nonablative
egimens improves leukemia control in a select pop-
lation of patients [10].
Our group has investigated the use of the combi-
ation of melphalan (M) and the purine analog ﬂu-
arabine (F) for the treatment of AML and high-risk
DS over the last decade. The rationale for the drug
ssociation relies on F-mediated inhibition of DNA
epair, triggered by exposure to the alkylating agent.
n addition, the purine analog is a potent immunosu-
ressive drug [11].
Here, we report long-term results of the reduced
ntensity regimen FM followed by allogeneic HSCT
or treatment of AML.
ATIENTS AND METHODS
ligibility Criteria
Patients with AML or high-risk MDS treated with
he combination of F and M 100, 140, or 180 mg/m2
FM100, FM140, or FM180) and allogeneic HSCT
sing bone marrow or peripheral blood progenitor
ells were included in this study. Transplants occurred
etween April 1998 and December 2003. Patients
eceived transplants from human leukocyte antigen
HLA)-compatible related donors or unrelated do-
ors, serologically matched for HLA-A and -B and
atched for HLA-DRB1 by high-resolution molecu-
ar methods. Grafts were depleted of erythrocytes as
ndicated for ABO incompatibility, but no patient re-
eived a T cell-depleted transplant. tPatients were prospectively accrued to 1 of 4 pro-
ocols utilizing the FM preparative regimen within the
tudy period. The ﬁrst study was designed to deter-
ine the toxicity and feasibility of FM180. The sec-
nd protocol compared FM180 to FM140, with the
ajor goal of reducing toxicity associated with
M180. A third study investigated the addition of
emtuzumab ozogamicin to FM140. For these studies,
atients were required to be older than 50 years of age
r have comorbidities rendering them ineligible for
yeloablative conditioning regimens. The 4th study
valuated FM100 with allogeneic HSCT for patients
lder than 55 years in ﬁrst remission (CR1). Patients
ho received a prior allogeneic hematopoietic trans-
lant were not included in this analysis. Fifty percent
f the patients in this cohort were previously reported,
ith shorter follow-up [10].
All patients were treated on protocols approved by
he institutional review board (IRB) or with IRB ap-
roval under the compassionate IND mechanism. All
atients provided written informed consent. The IRB
ranted permission for this analysis.
reparative Regimen
The conditioning regimen consisted of ﬂudara-
ine 25 to 30 mg/m2 for 4 to 5 days (transplant days
6 or 5 to 2) with melphalan 100 mg/m2 (n  13;
1.7%), 140 mg/m2 (n  46; 41.1%) or 180 mg/m2
n  53; 47.3%). Melphalan was given on day 2.
emtuzumab ozogamicin 2 or 4 mg/m2 was added in
6 cases (day 12). Antithymocyte globulin was given
o 31 patients receiving an unrelated donor. GVHD
rophylaxis consisted of tacrolimus and methotrexate
mg/m2 intravenously on days 1, 3, 6, and 11 after
ransplantation in all but 1 patient who received cy-
losporine. Tacrolimus doses were adjusted to main-
ain blood levels of 5 to 15 ng/dL during the ﬁrst 100
ays and then tapered as indicated depending on do-
or type, presence or absence of GVHD, and degree
f donor cell chimerism.
one Marrow and Peripheral Blood Stem
ell Procurement
Donor bone marrow or G-CSF primed peripheral
lood progenitor cells were procured using standard
obilization protocols and apheresis techniques. All
onors provided written informed consent. Bone mar-
ow procured from unrelated donors was obtained
hrough the National Marrow Donor Program ac-
ording to applicable guidelines. As required by the
ational Marrow Donor Program, donors provided
nformed consent at the donor center.
upportive Care
Infection prophylaxis during the peritransplanta-
ion period consisted of levoﬂoxocin, ﬂuconazole, and
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B. Oran et al.456cyclovir or valacyclovir. Filgrastim 5 g/kg was ad-
inistered subcutaneously daily from transplant day 7
ntil recovery of the granulocyte count to 1.5 
09/L for 3 days. Patients were screened biweekly for
ytomegalovirus antigenemia with preemptive use of
anciclovir in the event of a positive assay. Blood
roduct transfusions were irradiated and ﬁltered to
emove leukocytes. After recovery of the neutrophil
ount to 1.0  109/L blood, patients received pro-
hylaxis against Pneumocystis carinii infection using
rimethoprim-sulfamethoxazole given orally twice
eekly or pentamidine intravenously every 3 weeks.
ngraftment and Chimerism
Engraftment was deﬁned as the ﬁrst of 3 consec-
tive days with an absolute neutrophil count 0.5 
09/L. Failure to engraft by day 30 was considered
rimary graft failure. Platelet engraftment was deﬁned
s the ﬁrst of 7 consecutive days that the platelet count
xceeded 20  109/L without transfusion support.
himerism analysis was performed on days 30 and 100
ost-transplantation, and every 3 months thereafter.
himerism was monitored using restriction fragment-
ength polymorphisms at the AY-29 or YNH24 loci
12], conventional cytogenetic analysis by G-banding,
r ﬂuorescent in situ hybridization studies in sex-
ismatched cases for Y chromosome, and by DNA
icrosatellite polymorphisms by polymerase chain
eaction with D6S264, D3S1282, D18S62, and
3S1300 ﬂuorescence-labeled primers.
efinitions
CR prior to HSCT was deﬁned as a normocellular
one marrow containing5% blasts, with evidence of
ormal maturation of other marrow elements, absence
f peripheral blood blasts, and a platelet count greater
han 100  109/L. CR after transplantation was de-
ned using the same criteria except for platelet count,
ith donor cell engraftment. Response evaluation was
erformed on day 30 after HSCT, and every 3 months
uring the ﬁrst 2 years.
For patients not in CR, disease status was catego-
ized as relapsed/refractory, primary induction failure
nd untreated disease (eg, chemotherapy naïve MDS).
n addition, patients with active disease were catego-
ized in 2 subgroups: those with and without circulat-
ng blasts.
AML cytogenetic abnormalities were grouped ac-
ording to published criteria adopted by the SWOG
13] and deﬁned as follows: “favorable risk” was
nv(16)/t(16;16)/del(16q) or t(15;17) with any addi-
ional abnormalities, or t(8;21); “intermediate risk”
as 8, Y, 6, del(12p), or normal karyotype; and
poor risk” was 5/del(5q), 7/del(7q), inv(3q), abn
1q, 20q, or 21q, del(9q), t(6;9), t(9;22), abn 17p, and
omplex karyotype deﬁned as 3 or more abnormali- dies. Cytogenetic subgroups for MDS were deﬁned as
ollows: “favorable risk” group was normal, Y alone,
el(5q) alone, del(20q) alone; “poor risk” group was
omplex (ie, 3 abnormalities) or chromosome 7 anom-
lies; and “intermediate risk” group was other abnor-
alities [14]. Mixed chimerism was deﬁned as the
resence of any detectable (1% or greater) recipient
NA or cells in addition to donor-derived DNA or
ells.
tatistical Methods
Overall survival was measured from the day of
llogeneic stem cell infusion (day 0) until death from
ny cause, with censoring performed at the date of last
ontact. Actuarial survival was estimated using the
ethod of Kaplan Meier. Time to disease progression
as measured from day 30 until relapse for patients
hat were in CR 1 month after transplantation. Death
f any cause other than relapse or disease progression
as scored as nonrelapse mortality. Deaths occurring
uring the ﬁrst 30 days prior to disease reassessment
ere scored as “early deaths”, and considered as non-
elapse mortality. The incidence of disease progres-
ion, nonrelapse mortality, acute and chronic GVHD
as estimated using the cumulative incidence method
ccounting for competing risks. Cox proportional haz-
rds model was used to evaluate prognostic factors for
urvival and disease progression in univariate and mul-
ivariate analysis. Statistical signiﬁcance was deter-
ined at the 0.05 level. Analysis was performed using
TATA (StataCorp. 2001; Stata Statistical Software:
elease 7.0. College Station, TX: Stata Corporation).
ESULTS
atient and Disease Characteristics
Patient, disease, and treatment characteristics are
ummarized in Table 1. There were 112 patients that
et the inclusion criteria for this review. Median age
t HSCT was 55 years (range, 22-74 years). Disease
tatus was CR in 30 (26.8%), relapsed/refractory in 43
38.4%), and primary induction failure in 32 (28.6%)
atients. Seven patients with MDS (6.3%) were che-
otherapy-naïve prior to HSCT. Karyotype was
oor, intermediate, and favorable prognosis in 42.9%,
1.8%, and 2.7% of the cases, respectively. Karyotype
as unknown in 3 patients. Thirty patients had MDS
ith high-risk karyotype or intermediate to poor risk
isease based on the International Prognostic Scoring
ystem [15]. Most MDS patients had chemotherapy-
efractory disease (n  16, 53.3%).
Median time from diagnosis of MDS or AML to
llogeneic HSCT was 11 months (range, 0.9-176
onths). Patients in CR1 underwent allogeneic
SCT after a median of 4.7 and 7.2 months after
iagnosis, respectively, for recipients of related or un-
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HSCT for Treatment of High-Risk Acute Myelogenous Leukemia 457elated donor transplants. Median duration of CR1 for
0 patients receiving allogeneic HSCT in second or
hird CR was 10.8 months (range, 2-58.5 months).
atients with relapsed/refractory disease at HSCT
ad a median CR1 duration of 9 months (range, 1.3-
6.7 months). The median time interval between ﬁrst
elapse and transplantation was 2.5 and 5.1 months for
elated and unrelated donor transplants, respectively.
elphalan Dose
There was no difference in survival and risk of
rogression between subgroups of patients treated
ith FM140 versus FM180. Patients were therefore
rouped and analyzed together. FM100 was used
ostly for patients in CR1, and any effect of melpha-
an dose in that subgroup could not be investigated
iven the small numbers of patients in CR1 treated
ith FM140 and FM180. Figure 1A and B shows the
omparable results of FM100, 140, and 180 in patients
n CR at HSCT and FM140 and FM180 in patients
ith active disease at HSCT.
Overall, patient and disease characteristics were
able 1. Patient, Disease and Donor Characteristics
Variable Number %
ge
>55 years 50 44.6
<55 years 62 55.4
ender
Female 43 38.4
Male 69 61.6
iagnoses
AML 82 73.2
MDS 30 26.8
rior autologous HSCT
No 98 87.5
Yes 14 12.5
aryotype Group
Poor risk 48 42.9
Intermediate risk 58 51.8
Favorable risk 3 2.7
Unknown 3 2.7
isease status at HSCT
CR (CR1/CR2 or CR3) 30 (20/10) 26.8
Relapse 43 38.4
Primary induction failure 32 28.6
Untreated 7 6.3
resence of circulating blasts at HSCT
Active disease without circulating blasts 48 42.9
Active disease with circulating blasts 34 30.4
onor type
Unrelated 53 47.3
Related 59 52.7
tem cell source
Peripheral Blood 56 50
Bone Marrow 56 50
SCT, hematopoietic stem cell transplantation; CR, complete re-
mission; CR1, ﬁst complete remission; CR2-3, second or third
complete remission.imilar in the melphalan subgroups, except for the sssociation of CR1 with FM100 (10 of 13 patients in
R1), and the older median age (59 versus 53 years) in
he FM100 subgroup compared to FM140 or FM180
ubgroups. The proportion of patients in remission at
SCT was 77% (FM100) versus 19% (FM140 and
80). Gemtuzumab ozogamicin was added to FM140
nder a phase I/II study, without inducing excessive
oxicity. All recipients of the drug (n  16) had re-
apsed disease at study entry.
ngraftment and Chimerism
Neutrophil recovery was documented in 105
94%) of the patients, while 7 patients died without
vidence of engraftment. Median time to a neutrophil
ount 0.5  109/l was 13 days (range, 8-28 days).
our patients had primary graft failure (all recipients
f unrelated donor HSCT), and 3 had secondary graft
oss. Platelet recovery to 20  109/l occurred in 90
ases (86%), at a median time of 20 days (range, 7-139
ays). A month after transplantation, median donor
himerism was 100%, and 8 of 99 evaluable patients
ad mixed chimerism (8%). Two of the mixed chime-
as subsequently lost their graft, and 3 had disease
rogression within the ﬁrst 100 days post-transplan-
ation; these patients received donor lymphocyte in-
usion or second allogeneic HSCT, 1 converted to
omplete donor chimera, and 2 remained mixed chi-
eras in CR on day 100.
esponse, Relapse, and Overall Survival
Ninety-seven patients (87%) were in CR 30 days
ost-transplantation. Early death occurred in 8 cases,
nd 7 did not respond and had persistent disease. The
R rate was 84% and 78%, respectively, for patients
ith relapsed/refractory disease and primary induc-
ion failure. Disease progression occurred in 19 of 67
29%) patients that achieved a CR after HSCT, at a
edian of 4.2 months. Among patients transplanted in
R, disease progression occurred in 6 of 30 patients
20%) at a median of 6.8 months after transplant.
ost relapses occurred during the ﬁrst 6 months post-
reatment, and all but 3 patients relapsed within a year
fter transplantation. Only 1 subject relapsed more
han 2 years after treatment. The 2-year cumulative
ncidence of disease progression for the whole cohort
as 25%. The 2-year cumulative incidence of relapse
as 20%; 15%, and 46%, respectively, for patients in
R at transplantation, and for patients with active
isease with and without circulating blasts (Figure 2).
In univariate analysis, presence of circulating
lasts was the only signiﬁcant risk factor for disease
rogression (Table 2 and 3), with a hazard ratio (HR)
f 3.7 compared to patients in CR at transplantation
95% conﬁdence interval [CI], 1.4-9.8; P  0.01). No
igniﬁcant difference for progression of disease was ob-
erved between patients in CR versus those with active
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B. Oran et al.458isease at transplantation without circulating blasts
HR  1.1, 95% CI  0.4-3.2, P  0.9). Development
f acute or chronic GVHD did not prevent relapse.
The median follow-up of 43 surviving patients is
9.4 months (range, 13.1-87.7 months), while the me-
igure 1. (A) Patients in complete remission at transplantation: su
howed by melphalan dose in the conditioning regimen (solid line,
g/m2; spaced dashed line, FM140 mg/m2). Patients receiving FM
M180 (59 versus 43 years, P  .002). Most patients in the FM10
ere mostly in second remission. Differences in outcomes were not
urvival, cumulative incidence of disease relapse, and nonrelapse mor
ashed line, FM 140 mg/m2). Differences in outcomes were not stFigure 2. Cumulative incidence of disease progreian survival of 69 patients (62%) that have died was
1.3 months. The 2-year overall survival for the whole
ohort is 44%. One patient was lost to follow-up.
ost deaths (90%) occurred within the ﬁrst 2 years
fter transplantation. Estimates of 2-year overall sur-
cumulative incidence of disease relapse, and nonrelapse mortality,
bine [F] and melphalan [M] 100 mg/m2; tight dashed line, FM180
complete remission were older than those treated with FM140 or
oup were in ﬁrst remission, while recipients of FM140 or FM180
cally signiﬁcant. (B) Patients with active disease at transplantation:
howed by melphalan dose (tight dashed line, FM180 mg/m2; spaced
lly signiﬁcant.rvival,
ﬂudara
100 in
0 subgr
statisti
tality sssion by disease status at transplantation.
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HSCT for Treatment of High-Risk Acute Myelogenous Leukemia 459ival were 66% for those in CR, 40% for patients not
n CR but without circulating blasts, and 23% for those
ith active disease and circulating blasts (Figure 3).
In univariate analysis, the following variables were
ound to be signiﬁcantly associated with improved
urvival: less extensive disease at HSCT, intermediate
isk karyotype, and absence of grade II-IV acute
VHD (Table 3). Only disease status and absence of
rade II-IV acute GVHD remained statistically sig-
iﬁcant in the multivariate analysis. Compared to pa-
ients in CR, patients with active disease at HSCT had
able 2. Risk Factors for Disease Progression for Patients in CR 30 Da
Variables No of Pati
ge
<55 years 53
>55 years 44
onor
Related 52
Unrelated 45
uration of 1st CR1
<12 months 53
>12 months 17
isease status at HSCT
CR 30
Active disease without circulating blasts 41
Active disease with circulating blasts 26
aryotype risk group
High 42
Intermediate 51
GVHD II-IV2
GVHD2,3
R, hazard ratio; CI, conﬁdence interval; HSCT, hematopoiet
graft-versus-host disease.
1st CR and untreated cases were excluded; 2time dependent varia
able 3. Risk Factors for Overall Survival After Transplantation
Variables N HR
ge
<55 years 62
>55 years 50 0.9
onor
Unrelated 53 1.5
Related 59
uration if 1st CR1
<12 mo 67 1.5
>12 mo 18
isease status at HSCT
CR 30
Active disease without circulating blasts 48 2.0
Active disease with circulating blasts 34 3.5
aryotype Risk Group
High 48 1.6
Intermediate 58
GVHD II-IV2 3.1
GVHD2,3 1.7
R, hazard ratio; CI, conﬁdence interval; HSCT, hematopoiet
graft-versus-host disease.1st CR and untreated cases were excluded; 2time dependent variable; 3oorse survival (HR 2.8; 95%CI  1.4-5.3; P  .002,
or patients with circulating blasts, and HR 1.8; 95%
I  0.9-3.5, P  .06, for patients without circulating
lasts). Among patients with active disease, presence
f peripheral blood blasts was associated with worse
urvival (HR  1.7, 95% CI  0.99-2.8, P  .06).
evelopment of grade II-IV acute GVHD was asso-
iated with signiﬁcantly shorter survival (5.3 months
ersus 43.8 months for patients without grade II-IV
cute GVHD; HR 2.8 as a time-dependent variable,
5% CI  1.8-4.6, IP  .001).
r Transplantation
HR 95% CI Univariate P Value
1.2 0.5-2.5 0.7
0.8 0.4-1.9 0.6
1.1 0.4-3.1 0.9
1.1 0.4-3.2 0.9
3.7 1.4-9.8 0.01
1.7 0.7-3.7 0.2
1.2 0.5-2.8 0.6
0.3 0.1-1.3 0.1
cell transplantation; CR, complete remission; aGVHD, acute
utcome from day 100; cGVHD, chronic graft-versus-host disease.
variate Analysis Multivariate Analysis
95% CI P HR 95% CI P
0.6-1.5 0.7
0.9-2.4 0.1
0.8-2.9 0.24
1.0-3.9 0.04 1.8 0.9-3.5 0.06
1.8-6.9 <0.001 2.8 1.4-5.3 0.002
1.0-2.7 0.05
1.9-5.1 <0.001 2.8 1.8-4.6 <0.001
0.9-3.2 0.12
cell transplantation; CR, complete remission; aGVHD, acuteys Afte
ents
ic stemUni
ic stemutcome from day 100; cGVHD, chronic graft-versus-host disease.
GG
o
d
d
o
p
(
d
m
(
o
d
c
r
d
c
t
r
o
c
q
t
G
w
o
d
i
c
f
t
(
N
5
1
f
2
t
p
o
s
p
.
o
t
d
i
w
a
p
D
F
a
a
t
b od blas
B. Oran et al.460VHD and Causes of Death
The cumulative incidence of grade II-IV acute
VHD was 39% (n  46), with a median time to onset
f 29 days (range, 7-97 days). Chronic GVHD was
ocumented in 51 of 81 patients surviving beyond 100
ays, with a cumulative incidence of 49%. Seventy-
ne percent of the cases had extensive disease. The
resentation was de novo in 22 (43.1%), relapsed in 18
35.3%) and progressive in 11 (21.6%) patients. Me-
ian time to development of chronic GVHD was 6.1
onths (range, 3.3-33.2 months).
The most common causes of death were GVHD
n  28), relapse (n  21), infection (n  10) and
thers including severe hemorrhage, veno-occlusive
isease and multiorgan failure (n  10). Acute or
hronic GVHD was the cause of death of 36% of the
ecipients of unrelated donor transplant, while 17%
ied of relapse, 10% of infections, and 6% of other
auses. Among recipients of related donor transplants,
hese proportions were 15%, 20%, 7%, and 12%,
espectively. In the group of 46 patients that devel-
ped acute grade II-IV GVHD, acute GVHD was the
ause of death in 11, while 14 patients died subse-
uently of chronic GVHD.
There were 15 deaths beyond the ﬁrst year post-
ransplant, due to disease progression (n  5), chronic
VHD (n  5), and infection (n  3). Cause of death
as unknown in 2 cases. Late deaths due to relapse
ccurred only among patients transplanted with active
isease at HSCT. Patients in CR at transplant died of
igure 3. Overall survival by disease status at transplantation. Kaplan-M
t transplantation. Estimates of 2-year overall survival were 66% for tho
nd 23% for those with circulating blasts. P  .0007 for the overall co
ransplantation had worse survival (P  .02, for the comparison with
lasts). Among patients with active disease, presence of peripheral blonfection (n  2), GVHD (n  1) and other compli- aations (n  2). Late deaths (occurring after 3 years
rom transplantation) were due to GVHD and infec-
ion (n  4), relapse (n  1), and unknown cause
n  1).
onrelapse Mortality
Cumulative incidence of NRM in this cohort was
4% at last follow-up. Cumulative incidence of day
00 and 2-year NRM was 0% and 20%, respectively,
or patients in CR at HSCT. These numbers were
0% and 30% for patients receiving a related donor
ransplant with active disease, and 35% and 56% for
atients treated with a matched unrelated donor with-
ut CR at transplantation.
Patients with active disease at transplantation had a
igniﬁcantly higher risk of nonrelapse mortality com-
ared to patients in CR at transplantation (HR 3, P
02) (Figures 1A, 1B and 4). The impact of donor type
n nonrelapse mortality was correlated to disease sta-
us, as described above. The use of unrelated donors
id not increase the risk of treatment-related mortal-
ty among patients in CR, but it did so among patients
ith active disease at transplantation. Age, karyotype,
nd use of FM140 versus FM180 did not affect the
robability of nonrelapse mortality.
ISCUSSION
AML and MDS are diseases of the elderly, char-
stimates of overall survival of all patients, as a function of disease status
mission, 40% for patients with active disease without circulating blasts,
on. Compared to patients in remission, patients with active disease at
with circulating blasts, and P  .06, for patients without circulating
ts was associated with worse survival (P  .06).eier e
se in re
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HSCT for Treatment of High-Risk Acute Myelogenous Leukemia 461f morbidity and mortality with current available che-
otherapy [16]. Allogeneic hematopoietic transplan-
ation produces signiﬁcantly higher remission rates
han chemotherapy, but only a small fraction of all
atients with these diseases receive a transplant, pri-
arily because of concerns regarding the toxicity of
he preparative regimen and treatment related mor-
idity and mortality. Therefore, a major goal is to
ncrease the applicability of the transplantation to
lder or medically inﬁrm patients. With the use of
onablative preparative regimens, the median age of
atients treated with related or unrelated donor
SCT is increasing, and several groups have reported
eries of patients in the 6th decade of life [6,7,17,18].
ince 1996, when the ﬁrst reports of RIC regimens
ere being presented in the meetings of the American
ociety of Hematology, the use of this therapeutic
odality has increased dramatically with now almost
0% of allografts being done after a reduced intensity
egimen primarily being used in older patients [19].
Initial reports all demonstrated the feasibility and
hort-term efﬁcacy of RIC allografting in patients
ith AML/MDS. This report demonstrates that long-
erm disease control can be achieved with this thera-
eutic modality. The patient population in this series
ad many unfavorable patient and disease character-
stics. The majority had refractory disease with inter-
ediate or high-risk karyotype. Median age was 55
ears, with 25% of patients older than 60 years of age.
ore than 70% of patients had active disease, consis-
ent with the low complete remission rate in this age
ange [3,4].
In this report we conﬁrm the safety and efﬁcacy of
he combination of the FM combination. Given the
Figure 4. Cumulative incidence of nonrelapse morta% 100-day and 20% 2-year NRM rate in patients cith a median age of 59 years transplanted in remis-
ion, FM would appear to compare favorably to other
IC regimens keeping in mind the lack of direct
omparisons among the available preparative regi-
ens. However, nonrelapse mortality was high in sub-
ets of patients, such as those with active disease in
hich NRM was 20%-35% at 100 days and 35%-56%
t 2 years.
Disease status at the time of transplant was the
ingle most important prognostic factor for survival
nd disease progression. Development of moderate to
evere acute GVHD had a strong deleterious effect on
urvival, but we failed to detect a protective effect of
GVHD on disease progression or overall survival as
ecently reported in a study with conditioning regi-
en of 2 Gy TBI and F [20]. However, another study
sing 8 Gy TBI and F showed results similar to ours
21]. Although this difference may be partially ex-
lained by the different conditioning regimens admin-
stered, the protective effect of cGVHD may be more
ifﬁcult to detect in a cohort of AML and MDS only
atients, because these diseases are less sensitive to the
VL phenomenon. In addition, older patients are less
ikely to tolerate GVHD-related complications such
s steroid side effects, infections, and delayed immune
ecovery, which may negate the potential beneﬁt of a
aximized GVL effect.
Similar outcomes were observed after FM140 and
M180. Nonlethal toxicity, however, was higher with
M180, and we do not recommend that regimen cur-
ently given the lack of evidence indicating improved
fﬁcacy. More caution is recommended when analyz-
ng the use of FM100, given that 77% of the small
umber of patients in that subgroup was in ﬁrst CR in
higher for patients transplanted with active disease.ontrast to 19% of the remaining patients. Bearing in
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B. Oran et al.462ind these considerations, 2-year survival of FM100
ecipients is greater than 60%. We continue to inves-
igate the use of FM100 for older patients in ﬁrst CR,
hile patients with more advanced stages of disease
re treated with FM140-based regimens.
The issue of optimal intensity of preparative regi-
ens for advanced age patients is far from resolved.
onsiderations must be made for functional status and
he presence of comorbidities. It is possible that the use
f comorbidity indices may help identify patients in the
ate 50’s and early 60’s that could be treated with higher
ntensity regimens [22]. Extent of prior treatment, donor
ype, and disease status must be considered.
Improvements in GVHD prevention and treatment
re clearly needed, especially for recipients of unrelated
onor transplants. Use of high-resolution allele level
atching for class I and II loci is likely to decrease
VHD rates and improve nonrelapse mortality.
Our data would suggest that older age cannot be
he sole reason for denying allogeneic HSCT to a
atient with myeloid leukemia. Major causes of mor-
ality remain GVHD and relapse, and every effort
hould be made to enroll older patients in clinical
rials investigating novel strategies to address these
roblems. Patients with active disease at transplanta-
ion should be considered for novel post-transplant
nterventions designed to prevent relapse.
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